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Abstract: Currently, no pharmaceuticals for the etiological treatment of degenerative protein-
misfolding diseases (e.g., ALS, Alzheimer’s or prion diseases) are commercially available. 
Therefore, in this technical note theoretical considerations and practical approaches concerning 
the development of chaperone-based medications from medicinal plants (e.g., Ginkgo biloba) 
are reviewed and discussed in detail. Phytochaperones and other agents isolated from 
medicinal plants are proposed to serve as the general basis of drug development in protein-
misfolding diseases. 
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INTRODUCTION   
“Nature is the only book, which offers large contents on all leaves” (Johann Wolfgang von 
Goethe, 1749-1832). This citation of the famous poet and natural scientist reflects that natural 
sources as plants should be consulted in order to find answers to problems concerning human 
health and welfare. Medicinal plants, for example, may be an important option for developing 
drugs from natural bioorganisms for the treatment of different diseases. 
 
Despite enormous economical, technical and scientific progress in the past years, fundamental 
developments for the accomplishment of important challenges of mankind concerning the 
effective treatment of several progressive degenerative and neurodegenerative diseases (e.g., 
ALS, Alzheimer’s or Parkinson’s diseases, et c.) are in its infacy. Many of them belong to the 
so-called “protein-misfolding diseases”. Furthermore, the pharmaceutical industries are not 
interested in developing certain innovative drugs to defeat these debilitating disorders because 
existing drugs, the so-called “blockbusters” may be more profitable than taking a chance on 
improving public health [1]. 
 
For these reasons the time has come to leave the conventional ways of thinking behind and to 
give unconventional ideas a chance to be realized, e.g., by developing medicines for common 
and rare diseases by non-profit laboratories. Furthermore, standardized analytical procedures 
(e.g., quantitative preparative native continuous polyacrylamide gel electrophoresis = QPNC-
PAGE) as well as modern biomolecular approaches (e.g., nuclear magnetic resonance = 
NMR or matrix-assisted laser desorption ionization time-of-flight mass spectrometry = 
MALDI-TOF-MS), successfully applied for identifying and isolating bioactive (metallo-) 
proteins or enzymes in complex protein mixtures could make an essential contribution to the 
development of innovative drugs from medicinal plants. Other important scientific fields like 
molecular biotechnology may contribute to produce a sufficient quantity of medicines for all 
people suffering from the mentioned diseases by using certain molecular farming procedures. 
 
It is a well-known fact that chemical and pharmacological chaperones have been found to be 
effective in preventing the misfolding of different disease-causing proteins, however, many of 
the compounds are highly toxic, reveal a lack of specificity or other unknown mechanisms of 
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action in vivo. This technical note is an attempt to introduce a new class of pharmacologically 
active proteins, namely the (metallo-) phytochaperones, proposed to be the key molecules for 
the etiological treatment of protein-misfolding diseases (PMD), and to motivate medicinal, 
pharmaceutical and biochemical researchers worldwide to apply the methodological 
approaches presented in this study for developing chaperone-based medications. 
MEDICINAL PLANTS AND PROTEIN-MISFOLDING DISEASES   
Drug discovery from medicinal plants is a challenging field because it involves a multifaceted 
approach combining botanical, phytochemical, biological, and analytical techniques [2 - 37]. 
Well-known plants used in Traditional Chinese Medicine (TCM), Japanese, Ayurvedic and 
European Medicine relevant to the management of Morbus Alzheimer and other cognitive 
disorders are listed in Table 1 [2, 17, 18, 26, 32]. For example, standardized plant extracts 
from green leaves of the Ginkgo biloba tree are generally accepted in the treatment of AD [3, 
4, 10, 17, 20, 32]. Through the antioxidant properties of its flavonoids these extracts may be 
able to protect hippocampal cells against toxic effects induced by amyloid ß (Aß) peptides [3]. 
An increase in the activity of the antioxidant enzymes, catalase and superoxide dismutase 
were further observed in rats treated with EGb 761 Ginkgo extract [4]. Another plant used in 
the Ayurvedic medicine termed Bacopa monniera reduces Aß deposits in brain of AD animal 
model [8]. 
 
AD and many other neurodegenerative diseases are associated with disturbances of metal ion 
metabolisms and oxidative stresses postulated to be a downstream effect of abnormal Aß - 
metal ion interactions [7, 15, 21, 22, 25, 27]. Therefore, the metal ion homeostasis in a cell 
has to be regulated strictly by metallochaperones and other biomolecules (e.g., 
metallothioneins). For example, copper chaperones for superoxide dismutase (CCS) are 
essential metalloproteins for protecting and guiding copper ions to superoxide dismutase 
(SOD). Via specific protein-protein interactions SOD is activated by incorporating a Cu
+
 ion. 
As properly folded SOD molecules are very important antioxidants, these metal species 
contribute to a decreasing oxidative stress in cells [21, 22]. Therefore, metal chelation and 
antioxidants may be a potential therapy against neurodegenerative diseases [6, 7, 10, 15, 25]. 
Novel therapeutic strategies for the treatment of PMD are introduced by a deep insight review 
of Rochet [33]. 
 
Despite several therapeutic approaches, no preventive measure and effective treatment for 
PMD, especially Alzheimer’s disease, is currently available [27]. Furthermore, vast majorities 
of psychoactive drugs are not natural products or are not derived from bioactive constituents 
of medicinal plants [26]. Therefore, some researchers demand to use natural plant extracts as 
possible protective agents of brain aging [3] and dementia therapy [32]. 
 
Plant extracts are multicomponent mixtures consisting of the bioactive main ingredients and 
secondary plant compounds which may interact with each other in a synergistic manner [9, 
13, 20]. Drying and storing of medicinal plants are critical steps in the production processes of 
natural extracts and phytomedicines because the chemical stability of the bioactive ingredients 
may be adversely affected by the formation of unwanted artefacts [5]. As nature is the best 
combinatorial chemist and possibly has answers to all diseases of mankind [18] it is assumed 
that pharmacologically active ingredients in addition to the well-known plant flavonoids and 
terpenoids, namely proteins and enzymes, could be isolated and identified in medicinal plants 
for the effective treatment of several PMD. According to Table 1. especially extracts from the  
green leaves of Ginkgo biloba and other plants may contain bioactive metalloproteins for the 
treatment of AD or other degenerative disorders. 
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A majority of PMD are being considered caused primarily due to the imbalance between pro-
oxidant and antioxidant homeostasis [35]. An ideal therapeutic drug to dissolve Aß amyloid in 
AD, for example, would involve a compound selective for Cu
1+
, Zn
2+
 and Fe
3+
, but does not 
sequester Mg
2+
 and Ca
2+
 [7]. For example, Cu chaperones are a ubiquitous class of proteins 
that play a significant role in both Cu delivery and cellular protection against copper exposure 
under normal metabolic conditions by delivering and binding metal ions [16, 29]. Therefore, 
bioactive Cu chaperones may be the basis for developing novel lead molecules in the 
treatment of PMD. 
 
It is a well-known fact that improperly folded CCS may play an important role in the etiology 
of Alzheimer’s disease and other PMD. Therefore, the dysregulation of metal ion homeostasis 
and severe oxidative stresses in bioorganisms may occur [21, 22]. Furthermore, under non-
physiological conditions a reduced enzyme activity of SOD and apo-SOD (apoenzymes) can 
be detected and quantified in blood of animals [37]. The apoenzymes are referred to as 
unfolded molecules. Therefore, it may be a necessary and helpful therapeutic approach to 
balance the metal ion homeostasis by activating unfolded SOD in blood of diseased 
bioorganisms. For these purposes, exogenous plant copper chaperones for SOD (pCCS) 
isolated from medicinal plants may be the lead molecules for an effective treatment of PMD. 
The pCCS activators may be able to recover the balance between pro-oxidant and antioxidant 
homeostasis of bioorganisms by copper ion transfer affecting the mechanism and speed of 
folding for the rapid achievement of the bioactive 3-D conformation of human SOD (hSOD), 
and by binding uncomplexed metal ions (e.g., Cu, Zn or Fe) in blood or other biofluids of 
living organisms. 
DEVELOPMENT OF CHAPERONE-BASED MEDICATIONS   
For developing chaperone-based medications from medicinal plants the following procedures 
could be very promising. For these purposes, properly and improperly folded copper cofactor-
containing chaperones for superoxide dismutase present in blood samples of AD patients and 
probands have to be purified by innovative methods such as preparative native gel permeation 
chromatography (GPC) and QPNC-PAGE. The isolated metalloproteins of interest may be 
further elucidated by solution NMR spectroscopy. By applying an inductively coupled plasma 
mass spectrometry (ICP-MS) detection method for biometals, Fe, Cu, and Zn cofactors can be 
identified and quantified in the respective GPC and PAGE fractions. After electrophoretic 
separation improperly folded and bioactive metallochaperone proteins present in diseased or 
healthy blood can be resolved in the electrophergrams due to their different isoelectric points 
[19, 21, 22]. Bioactive and inactive metalloproteins can also be isolated and quantified in 
other organisms, e.g., model plants by using the same methods [21-24]. 
 
Therefore, these efficient methods may be applied successfully in the discovery of 
pharmacologically-active metallochaperone proteins in medicinal plants as presented in Fig. 
(1). In this figure the basic investigations of selected protein-protein interactions and 
metalloprotein detection procedures in complex biological systems are schematically 
presented. 
 
By incubating clinical biofluids (e.g., whole blood) with medicinal plant extracts (e.g., Ginkgo 
biloba), specific apoenzymes in a pathological blood sample (apo-SOD) might fold into their 
native conformation due to specific protein-protein interactions. Human SOD is a 
biomacromolecule with a molecular mass of about 32 kDa and might interact with the 
investigated plant CCS provided that pCCS has a similar molecular mass and structure and 
function compared to human CCS. The respective physiological effects can be studied using 
the proposed methods of the workflow schemes according to Fig. (1). 
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Plant extracts may be obtained by homogenising leaves of medicinal plants in liquid nitrogen 
by using mortars and pestles. The pulverized samples may be stored above liquid nitrogen or 
subsequently, extracted using a buffer solution. Medicinal plant extracts (e.g., Ginkgo biloba) 
are prepared under non-denaturing conditions by using a physiological buffer (e.g., 20 mM 
Tris-HCl, 1 mM NaN3, pH 7.2). Plant material and buffer solution may be homogenised in a 
ratio of 1:10 (m/m). After centrifugation of the plant homogenate the resulting supernatant is 
used for merging plant extract and blood. The incubation time is extended to a maximum of 
about 15 to 60 minutes at 4° C to avoid uncontrolled proteolytic processes, protein 
precipitation and destabilization of metal cofactor-containing proteins in this very complex 
system consisting of plant and human matrices. Hereafter, an aliquot of the protein mixture is 
chromatographed on a Sephadex G-50 SF column. Only a very small elution range (MW ≥ 30 
kDa for globular proteins) according to the void volume of the GPC method used is relevant 
for isolating some specific metal cofactor-containing proteins, CCS and SOD, by using 
QPNC-PAGE. The respective GPC conditions recommended for separating high molecular 
mass protein fractions are exemplary presented in Fig. (2). The complementary QPNC-PAGE 
parameters have already been listed in various articles or protocols [21-24, 34]. 
 
 
After GPC, a fraction of the void volume with the highest Cu concentration is separated by 
QPNC-PAGE. As result, physiological amounts of properly folded hSOD and pCCS may be 
isolated in a few specific PAGE fractions. Furthermore, the respective Cu cofactors of these 
biomolecules may be detected as “twin peaks” in the resulted electropherogram by using ICP-
MS. The ratio of peak areas of the copper species may indicate that certain medicinal plants 
may contain bioactive pCCS or not because in untreated blood of AD patients the hSOD and 
hCCS peaks may be very small (low Cu concentrations) while in incubated blood samples the 
peak areas involving hSOD molecules may rise in a QPNC-PAGE electropherogram 
corresponding to high Cu concentrations after a PAGE run. 
 
In order to develop chaperone-based medications from medicinal plants highly purified pCCS 
may be further isolated, elucidated and identified after the QPNC-PAGE run using a 
combination of 2-D PAGE (2-DE) followed by matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry and Bioinformatics presented in Fig. (3). The limitations of 
current proteomics technologies as referred to MALDI-TOF-MS and 2-DE are reviewed in 
[14]. An approach for identifying a high molecular mass metal protein in the model plant 
Arabidopsis thaliana by using these efficient methods is exemplary presented in [36]. 
 
The genetic code of the identified bioactive metallochaperone proteins in medicinal plants is a 
prerequisite for producing genetically modified plants (e.g., Nicotiana tabacum), designed to 
express the pCCS from medicinal plants as presented in Fig. (3). For the effective production 
of bioactive pCCS so-called “molecular farming” approaches are involved. Molecular farming 
is a challenging, new and promising technique using transgenic plants to produce foreign 
proteins as pharmaceutical ingredients. For these purposes plant growth and metabolism has  
to be optimized under standardized conditions in order to maximize protein concentrations in 
roots and shoots [30]. It is important to mention that this method is an alternative to the 
microbial expression systems enabling the correct folding of recombinant proteins [12, 31]. 
Of course, other clinical and pharmaceutical approaches as already described in literature [2 – 
37] have to be used for development of chaperone-based medications. 
CONCLUSIONS 
In this technical note different approaches including the molecular biotechnology, molecular 
farming, biology and analytical chemistry are proposed to be the initial steps for developing 
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chaperone-based medications from medicinal plants. Plant copper chaperones for superoxide 
dismutase (pCCS) extracted from natural bioorganisms are urgently needed for the etiological 
treatment of protein-misfolding diseases (e.g., ALS, Alzheimer’s or prion diseases) because 
pCCS may have the ability to activate human apo-superoxide dismutase (hSOD) in biofluids. 
The interrelationships between pCCS and hSOD in human beings and animals are essential 
for recovering the metal ion homeostasis and balance between pro-oxidative and antioxidative 
processes in the cells of these organisms. Therefore, this approach could help to prevent 
abnormal protein-misfolding processes and subsequent oxidative stresses occuring in 
bioorganisms. 
 
In addition to the well-known medicinal plants, e.g., Ginkgo biloba, other “living fossils” 
should be evaluated with respect to chelating and antioxidative properties in cells concerning 
the effective treatment of protein-misfolding diseases. For example, giant trees known as 
California Redwoods (e.g., Sequoia sempervirens), might be the natural sources of active 
metallochaperones or other important metal species. 
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Table 1. Traditional medicinal plants used for cognitive disorders 
 
Medicinal Plant         Uses, Pharmaceutical and Clinical Effects 
 
 
Centella asiatica L Strengthens nervous function and memory, 
enhancement of cholinergic activity and thus, 
cognitive function. 
 
Ginkgo biloba L  Improvement of memory loss associated with 
blood circulation abnormalties, favourable effects 
on neuronal cell metabolism, antioxidant activity, 
neuroprotective against β-amyloid toxicity in 
vitro. 
 
Melissa officinalis L Treatment of depression, hysteria and nervous 
insomnia, shows antioxidant effects. 
 
Polygala tenuifolia Willd  Used in TCM as a cardiotonic and cerebrotonic, 
as a sedative and tranquillizer, and for amnesia, 
forgetfulness, neuritis, nightmares and insomnia.   
 
Salvia lavandulaefolia Vahl.   Cholinesterase inhibition, antioxidant and  
Salvia officinalis L    oestrogenic activities in vitro. 
 
Salvia miltiorrhiza Bung  Treatment of blood circulation disorders, 
insomnia, neurasthenia and alleviation of 
inflammation. 
 
Withania somnifera (L) Dun  Important herb in Ayurvedic medicine, treatment 
of inflammatory conditions, such as arthritis. 
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Fig. (1). Workflow schemes in metalloproteomics and interactomics. 
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Fig. (2). Chromatogram showing the UV absorption profile of Arabidopsis supernatant separated on Sephadex 
G-50 Superfine. Gel volume: 500 mL; column length: 700 mm; column diameter: 30 mm; eluent flow rate: 12 
mL / hr; fraction volume: 8.0 mL; number of fractions: 95; sample volume: 5 mL; separation temperature: 4 °C; 
elution buffer: 20 mM Tris-HCl, 1 mM NaN3; pH 8.0. The peripheral tools used for preparative native GPC are 
listed in [24, 36]. The denoted molecular weights of the detected metal compounds are approximated values. 
Metal cofactors eluted in the range of the void volume (120 to 140 mL) of this method were identified and 
quantified by ICP-MS or GF-AAS [24, 36]. 
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Fig. (3). Workflow schemes in metalloproteomics and phytofarming. 
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